Professor Michael Schroeder is a Professor in Bioinformatics at the Biotechnology Center (BIOTEC) and Department of Computing at Technische Universität Dresden. He serves as Director of the Biotechnology Center since 2012, with specific periods as Director (2012-2014, 2019-2021), and Director of the Center for Molecular and Cellular Bioengineering (CMCB) from 2022-2023. He is also CSO of Transinsight.com since 2006 and co-founder of PharmAI GmbH since 2019. His research focuses on developing machine learning algorithms exploiting large protein structure and sequence data to improve diagnosis and treatment of disease. Key areas include: Computational drug repositioning using networks, structures, text, and ontologies Pancreas cancer drug and biomarker prediction through AI analysis of blood samples (90%+ accuracy) Antibiotic resistance analysis in wastewater E. coli through genomic variations Development of novel lead compounds for cancer chemotherapy resistance, autoimmune disease, and Chagas disease Prof. Schroeder's publication record demonstrates consistent application of network analysis, structural bioinformatics, and machine learning to solve biomedical problems, with particular emphasis on pancreatic cancer and drug repositioning. His work bridges computational approaches with experimental validation through collaborations with medical researchers. Notable achievements include: Publication of over 230 scientific papers Hirsch index over 45 on Google Scholar Two granted patents Development of PLIP, a widely used open-source tool for analyzing molecular interactions Co-founding pharmAI GmbH, focusing on structure-based drug-target prediction Prof. Schroeder has supervised over 25 PhD students, with 10 receiving distinctions. Eight former group members have become professors or group leaders. His lab is currently funded by multiple projects including Kiwi, Ebira, and Scads.ai from BMBF, as well as EU and DFG grants. The Schroeder Group maintains extensive collaborations worldwide, including Yves Moreau (Leuven) for autoimmune disease research, Gildardo Rivera Sanchez (Reynosa) for Chagas disease, and Christian Pilarsky (Erlangen) for cancer research, demonstrating his strong international network and interdisciplinary approach.




